Provides sample-management and genomic services to pharmaceutical and biotechnology companies, research hospitals, and academic and government institutions. Sells automated sample-storage systems and laboratory products to those customers.
10-K for FY2025, filed Dec 4, 2025Within our Sample Management Solutions segment, we operate as a single business unit offering end-to-end sample management products and…View ↗
Within our Multiomics segment, our genomic services business advances research and development activities by providing gene sequencing…View ↗
We have approximately 14,000 customers globally and believe we are well positioned to expand our customer base. We serve top pharmaceutical…View ↗
Automated Stores – Our automated stores product includes stand-alone systems that can store over 20 million samples in temperature ranges…View ↗
Azenta bills for sample-storage, genomic and support services, as well as products, under contracts with generally fixed amounts; payment generally comes within a year after the service or product is provided.
10-K for FY2025, filed Dec 4, 2025Products, including sales of automated cold sample management systems, consumables, instruments, spare parts, and software.View ↗
Services, including repairs, upgrades, diagnostic support, installation, as well as biological sample services such as DNA sequencing, gene…View ↗
Determine the transaction price. The transaction price of the Company’s contracts with its customer is generally fixed, based on the…View ↗
10-K for FY2025, filed Dec 4, 2025
FY2025 revenue by product or service ↗$593.8M
10-K for FY2025, filed Dec 4, 2025
$593.8M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Dec 4, 2025 |
29%
FY2022: 33%
|
Product, FY2025
$173.2M Sources
|
Sold outright |
|
Service
|
71%
FY2022: 67%
|
Service, FY2025
$420.6M Sources
|
Pharmaceutical and biotechnology companies, research hospitals, academic and government institutions, and biotech start-ups buy from Azenta. Most sales, including storage systems, storage services and genomic services, are direct; distributors help sell consumables and instruments and support sales in emerging markets.
10-K for FY2025, filed Dec 4, 2025
Not on paper. It lost $55.8M in FY2025, but brought in more cash than it spent: $38.3M of free cash flow.
10-Q for Q3 FY2026, filed Aug 6, 2026
$2.5MView ↗
10-Q for Q3 FY2026, filed Aug 6, 2026
Open tableView ↗
8-K, filed Oct 30, 2026
Under the License Agreement, Azenta and its controlled affiliates have acquired an exclusive, royalty-free license under Elegen’s…View ↗
8-K, filed Aug 24, 2026
On August 22, 2026, John P. Marotta resigned as President and Chief Executive Officer of Azenta, Inc. (the “Company”) and as a member of…View ↗
8-K, filed Jul 8, 2026
On July 1, 2026, Azenta Germany GmbH, a wholly owned subsidiary of the Company, completed the sale of the entire issued share capital of B…View ↗
Growing. Revenue grew 16% in 4 years, from $513.7M in FY2021 to $593.8M in FY2025, about 4% a year.
B Medical's place in the portfolio
The older report described B Medical as an addition to the cold-chain portfolio; the latest treats it as held for sale and excludes it from continuing operations.
10-K for FY2022, filed Nov 25, 2022 10-K for FY2025, filed Dec 4, 2025On October 3, 2022, we acquired B Medical Systems S.á.r.l and its subsidiaries, or B Medical, a market leader in temperature-controlled…View ↗
Our Company was founded in 1978 and became a leading automation provider and partner to the global semiconductor manufacturing industry. We…View ↗
Support through commercialization
The latest report says Azenta supports customers through commercialization, extending beyond the older report's stated span from research to clinical development.
10-K for FY2022, filed Nov 25, 2022 10-K for FY2025, filed Dec 4, 2025We are a leading global provider of life sciences sample exploration and management solutions for the life sciences market. We entered the…View ↗
We are a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences…View ↗
Competes with Hamilton, Liconic, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, BGI Genomics, Eurofins, Scientific, GenScript Biotech, Integrated DNA Technologies, Novogene, and Twist Bioscience
10-K for FY2025, filed Dec 4, 2025Given the breadth of the solutions and services offered by our Sample Management Solutions and Multiomics segments, we believe we have a…View ↗
Loading...